Breast Cancer Research

official impact factor 5.79
Search for
Advanced search
Breast Cancer Research
Tools

This article is part of the supplement: The Third International Symposium on the Molecular Biology of Breast Cancer

Poster Presentation

Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer

M Van Ghelue1, M Ingebrigtsen1, HMF Riise Stensland1, L Mæhle2, J Apold3, P Møller2, V Marton1 and C Jonsrud1

Author Affiliations

1 Department of Medical Genetics, University Hospital North Norway, Tromso, Norway

2 Section for Genetic Counselling, Cancer Genetics, The Norwegian Radium Hospital, Oslo, Norway

3 Centre for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

For all author emails, please log on.

Breast Cancer Research 2005, 7(Suppl 2):P1.05 doi:10.1186/bcr1092


The electronic version of this article is the complete one and can be found online at:


Published:17 June 2005

©

Poster Presentation

Standard PCR-based mutation detection strategies performed on the BRCA1 and BRCA2 genes of breast and ovarian cancer families are mostly aimed at identifying changes in the coding sequences and in the donor-acceptor splice sites. Hence, mutations in the promoter and the untranslated regions, and large rearrangements, are not detected by these methods. To assess the importance of BRCA1 and BRCA2 alterations that are neglected by standard screening methods, we monitored germline rearrangements in these genes using 'multiplex ligation-dependent probe amplification' technology [1]. One hundred and seventy-nine Norwegian breast and ovarian cancer families were screened for rearrangements in BRCA1 while 97 families were tested for aberrations in BRCA2. Whereas no rearrangements were detected in BRCA2, four distinct deletions were found in BRCA1. Those deletions originating by Alu-mediated homologous recombination include: exons 1–13, exons 3–16, exons 8–13 and exon 23, respectively. The large 23.8 kb deletion excluding exons 8–13 in BRCA1 has been found both in the French and British breast cancer population [2-4]. The deletions of exons 1–13, exons 3–16 and exon 23 have not been previously reported.

References

  1. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

    Nucleic Acids Res 2002, 30:e57. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  2. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S: Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions.

    Cancer Res 1999, 59:455-461. PubMed Abstract | Publisher Full Text OpenURL

  3. Gad S, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Pujol P, Frenay M, Gilbert B, Maugard C, Bignon YJ, et al.: Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.

    Oncogene 2002, 21:6841-6847. PubMed Abstract | Publisher Full Text OpenURL

  4. Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, Duncan PJ, Curtis CE, Robinson DO, Harvey JF, Cross NC: Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.

    Br J Cancer 2004, 91:1155-1159. PubMed Abstract | Publisher Full Text OpenURL